Abstract
Mendelian and early-onset severe psychiatric phenotypes often involve genetic variants having a large effect, offering opportunities for genetic discoveries and early therapeutic interventions. Here, the index case is an 18-year-old boy, who at 14 years of age had a decline in cognitive functioning over the course of a year and subsequently presented with catatonia, auditory and visual hallucinations, paranoia, aggression, mood dysregulation, and disorganized thoughts. Exome sequencing revealed a stop-gain mutation in RCL1 (NM_005772.4:c.370 C > T, p.Gln124Ter), encoding an RNA 3′-terminal phosphate cyclase-like protein that is highly conserved across eukaryotic species. Subsequent investigations across two academic medical centers identified eleven additional cases of RCL1 copy number variations (CNVs) with varying neurodevelopmental or psychiatric phenotypes. These findings suggest that dosage variation of RCL1 contributes to a range of neurological and clinical phenotypes.
Original language | English (US) |
---|---|
Pages (from-to) | 1706-1718 |
Number of pages | 13 |
Journal | Molecular Psychiatry |
Volume | 26 |
Issue number | 5 |
DOIs | |
State | Published - May 2021 |
Funding
Acknowledgements The authors are grateful for the participation of the families reported herein and Johnathan Hecht for assistance with human tissue. Human tissue was obtained from the NIH NeuroBio-Bank at the University of Maryland, Baltimore, MD. We acknowledge the referring clinicians for providing clinical samples and data used in this analysis. Support was provided by Stanley Center of the Broad Institute, Tommy Fuss Center for Neuropsychiatric Disease Research, Anne and Paul Marcus Family Foundation, Robin and Jonathan Klein Family, and NIH U54 HD090255 in support of the Boston Children’s Hospital IDDRC Molecular Genetics Core Facility. Additional work was supported by NIH F32 NS100033801 and K99 NS112604 to RS and R01 NS035129 to CAW. The authors thank the Centre for Applied Genomics and the University of Toronto McLaughlin Centre for technical support and funding. SWS holds the GlaxoSmithKline-CIHR Chair in Genome Sciences at The Hospital for Sick Children and the University of Toronto.
ASJC Scopus subject areas
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
- Molecular Biology